Draft Research Plan
Aspirin Use to Prevent Morbidity and Mortality From Preeclampsia: Preventive Medication
June 20, 2019
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
- Does aspirin reduce adverse maternal, perinatal, child, or combined health outcomes in pregnant persons at increased risk of preeclampsia?
- Does the effectiveness of aspirin for reducing adverse health outcomes vary by subpopulations defined by personal characteristics or preeclampsia risk factors?
- Does aspirin prevent preeclampsia in pregnant persons at increased risk for preeclampsia?
- Does the effectiveness of aspirin for reducing preeclampsia vary by subpopulations defined by personal characteristics or preeclampsia risk factors?
- What are the harms of aspirin use to prevent preeclampsia during pregnancy?
- Do the harms of aspirin use to prevent preeclampsia vary by subpopulations defined by personal characteristics or preeclampsia risk factors?
Contextual questions will not be systematically reviewed and are not shown in the Analytic Framework.
- Are there new evidence-based approaches for identifying patients at risk for preeclampsia?
- How might recent changes to the diagnostic criteria for preeclampsia and for adult hypertension affect the interpretation or applicability of existing evidence?
The Proposed Research Approach identifies the study characteristics and criteria that the Evidence-based Practice Center will use to search for publications and to determine whether identified studies should be included or excluded from the evidence report. Criteria are overarching as well as specific to each of the key questions (KQs).
|Populations||KQs 1, 2 (Efficacy): Pregnant persons at increased risk for preeclampsia based on:
||Nonhuman populations; nonpregnant persons; studies that only/exclusively include persons seeking fertility treatment; and other selected nongeneralizable populations|
|Disease/condition||Primary prevention of preeclampsia||Trials of aspirin aimed at preventing other complications of pregnancy (e.g., stillbirth)|
|Interventions||Aspirin (≥50 mg)||Nonaspirin antiplatelet medications or aspirin combined with other potentially active interventions|
|Comparisons||Placebo or no treatment||Any active substance or intervention (e.g., nonaspirin medication, dietary supplements, dietary change, bed rest, or weight loss)|
Potential treatment harms:
Potential treatment harms:
|Study Designs||KQs 1, 2 (Efficacy): Randomized, controlled trial
KQ 3 (Harms): Randomized, controlled trial or comparative cohort studies
|KQs 1, 2 (Efficacy): Any nonrandomized controlled trial
KQ 3 (Harms): Editorials, narrative review, commentary, postmarketing surveillance, or case reports
|Language||English||Languages other than English|